Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Lantern Pharma Inc. (LTRN : NSDQ)

• Company Description    Lantern Pharma Inc.is a biotechnology company. It develops medicines for multi-drug treatment resistance cancers focusing on prostate and ovarian cancers. The company's drug candidate consist LP-100, LP-300 and LP-184 which are in clinical stage. Lantern Pharma Inc.is based in Dallas, Texas. Number of Employees: 24

• Price / Volume Information    Yesterday's Closing Price: $3.54 Daily Weekly Monthly 20 Day Moving Average: 234,452 shares Shares Outstanding: 10.78 (millions) Market Capitalization: $38.18 (millions) Beta: 1.54 52 Week High: $6.12 52 Week Low: $2.55 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 5.04% 1.89% 12 Week 0.57% -12.82% Year To Date 10.97% 4.84%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1920 MCKINNEY AVENUE 7TH FLOOR - DALLAS,TX 75201 USA ph: 972-277-1136 fax: - ir@lanternpharma.com http://www.lanternpharma.com

• General Corporate Information    Officers Panna Sharma - Chief Executive Officer and President Donald J. Keyser - Chairman David R. Margrave - Chief Financial Officer Maria Maccecchini - Director Vijay Chandru - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 51654W101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 10.78 Most Recent Split Date: (:1) Beta: 1.54 Market Capitalization: $38.18 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.44 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.81 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.28 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 17.65% vs. Previous Quarter: 22.22% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -83.26 12/31/24 - -72.61 ROA 06/30/25 - - 03/31/25 - -70.65 12/31/24 - -63.37 Current Ratio 06/30/25 - - 03/31/25 - 4.86 12/31/24 - 5.83 Quick Ratio 06/30/25 - - 03/31/25 - 4.86 12/31/24 - 5.83 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 1.56 12/31/24 - 1.96 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©